ChoA Pharmaceutical Co Ltd

ChoA Pharmaceutical has a debt-to-equity ratio of 0.57, indicating a moderate reliance on debt financing, and a current ratio of 1.41, suggesting it has sufficient short-term assets to cover its liabilities. However, the company's liquidity position is rated as medium, and its net cash is negative after subtracting total debt, signaling potential short-term liquidity constraints.

The company reported a net loss of 1,528,391,030 KRW and an operating loss of 1,729,569,480 KRW in the latest period, with a return on equity of -3.87% and a return on assets of -2.01%. These figures are below the typical performance metrics for the pharmaceutical industry, which usually emphasizes strong R&D returns and stable revenue streams.

ChoA Pharmaceutical's revenue is concentrated in a single geographic market, South Korea, with no disclosed international operations. The company does not report segment-level revenue, but its business is entirely focused on pharmaceuticals.

The company's revenue is expected to remain under pressure in the near term, with no clear signs of improvement in profitability. The operating cash flow is negative at -2,339,262,360 KRW, and free cash flow is also negative at -1,097,742,420 KRW, indicating that the company is not generating sufficient cash from operations to fund its activities.

The risk assessment highlights liquidity concerns, with a medium risk rating. The company has a low dilution risk, but its capital structure is under stress due to negative cash flows and operating losses. No recent filings or transcripts indicate significant changes in strategy or operations.

The company's recent performance, including a negative EPS of -32.00 KRW, reflects ongoing challenges in its core business. No recent events or disclosures suggest a turnaround is imminent.

Free cash flow improved by 29.0% year-over-year, indicating better cash generation despite ongoing operational losses.

Operating income improved by 20.3% year-over-year, suggesting a narrowing of operational deficits compared to the prior period.

Net income improved by 29.1% year-over-year, reflecting a reduction in net losses relative to the previous fiscal year.

Cash conversion ratio of 1.53 exceeds the pharmaceutical cohort median of 0.95, indicating superior cash efficiency.

Debt-to-equity ratio of 0.57 is below the cohort median of 0.18, suggesting a relatively conservative leverage position.

Revenue declined by 5.4% year-over-year, signaling weakening top-line growth in the current fiscal period.

The company faces medium liquidity risk, which could constrain its ability to meet short-term obligations.